

Assessment of Type 2 Anti-Diabetes on *Barringtonia racemosa* (L.) Dichloromethane Extract in Streptozotocin (STZ) - Induced Diabetic Rats

Umaru IJ^{1,2*}, Umaru HA³ and Umaru KI⁴

¹Faculty of Resource Science and Technology, University of Malaysia Sarawak, Malaysia

²Department of Biochemistry, Federal University, Wukari, Nigeria

³Department of Biochemistry Moddibo Adama University of Technology Yola, Nigeria

⁴Department of Biochemistry, University of Maiduguri Borno state, Nigeria

*Corresponding author: Isaac John Umaru, Faculty of Resource Science and Technology, University of Malaysia Sarawak, Kota Samarahan, Malaysia, Tel: 168395004; Email: umaruisaac@gmail.com

Research article

Volume 3 Issue 5

Received Date: October 11, 2018

Published Date: November 01, 2018

DOI: 10.23880/ijbp-16000141

Abstract

Objective: Type 2 diabetes mellitus is a heterogeneous group of metabolic disorders characterized by persistent hyperglycaemia. The aim of this research work is to gather scientific information about the possibility to utilize the dichloromethane leaf extract of *Barringtonia racemosa* as an agent of antidiabetic drug.

Material and Methods: The Crude extract was obtained through serial extract of five solvents, Hexane, dichloromethane, ethyl acetate, chloroform and methanol while the Assessment of type 2 anti-diabetes was conducted on Streptozotocin (STZ) -induced diabetic albino rats and the data were analysed through one-way ANOVA software. Histopathological studies of the pancreas and kidney were made to get evidence of the β -cell performance and the renal tissue respectively.

Results: The streptozotocin (STZ) induced diabetic rats treated with the Dichloromethane extract experienced an antidiabetic effect and the histopathologic observations showed increasing of the granulated β -cell at $p < 0.001$) and no renal tissue damage in the tested rats.

Conclusion: The result of this study revealed that the dichloromethane crude extract of *Barringtonia racemosa* could be utilized as an agent source of type 2 anti-diabetes.

Keywords: *Barringtonia racemosa*; Dichloromethane; Streptozotocin; Diabetic; Rats

Abbreviations: T2DM: Type II Diabetes Mellitus; WHO: World Health Organization; T1D: Type 1 Diabetic; STZ: Streptozotocin.

Introduction

Type II diabetes mellitus (T2DM) is a fast-growing epidemic affecting people globally. Furthermore, multiple complications and co-occurring with a primary disease are associated with T2diabetes. Lifestyle modifications along with pharmacotherapy and patient education are the main stay of therapy for patients afflicted with T2DM. Western medications are frequently associated with severe adverse drug reactions and high costs of treatment. However, herbal medications have long been used in the treatment and prevention of T2DM in traditional medicine which was presumed to avert this treat of health around the globe. This disorder is a chronic metabolic menace characterized by absolute or relative deficiencies in insulin secretion or insulin action associated with chronic hyperglycaemia and disturbances of carbohydrate, lipid and protein metabolism [1]. The disease is of three types recognized by the World Health Organization (WHO) such as (i) type 1 diabetes (insulin-dependent) (ii) type 2 diabetes (non-insulin-dependent) and (iii) gestational diabetes. The β -cells in the pancreas are the key players in this disorder called glycaemic homeostasis. The glucotoxicity, lipotoxicity, inflammatory mediators and incretin were reported to modulate function and survival of β -cell [2]. Besides, oxidative stress is thought to be a major risk factor on the onset and progression of diabetes [3]. Both type-1 and type-2 diabetes are associated with increased formation of free radicals and decreased antioxidant potential [4]. Thus, T2DM accounts for over 90% of cases globally [5-7]. According to the World Health Organization (WHO), in 2011, approximately 364 million people globally suffer from diabetes (DM), with projections that DM-related deaths will double from 2005 to 2030 [8].

Diabetes being a common disease in the developed and developing countries. According to a WHO report in 2011, approximately 360 million people globally suffer from diabetes. The epidemic is more pronounced in developing countries such as Malaysia, Nigeria respectively because of their feeding habits. As per

reports of the WHO, 32 million people of Malaysia had diabetes. The Malaysians would have a total number of 2.48 million diabetics compared to 0.94 million in 2000 that is about 164% increase. It is expected that more people in Malaysia will be affected by diabetes in the near future [9].

In the study of this diabetes diseases there are several animal models available to test for the mechanisms of diabetic complications, most of the studies on diabetic in animal models are largely restricted to type 1 diabetic (T1D) conditions [10,11]. In this context streptozotocin (STZ) [12-14] or alloxan-induced diabetic models are extensively used to study the diabetic among scientist and both these models mimic the T1D in humans. It was reported that oxidative stress appears to be a major factor in the development of other diseases in T1D, along with the activation of polyol pathway and non-enzymatic glycation [11,12,15].

Thus streptozotocin (STZ) induced rat model is one of the most frequently used for T2D-like models [16-18] which mimics human diabetes [19]. Previous studies on this model were found to have characteristics of pancreatic beta-cell destruction followed by beta-cell regeneration and glucose intolerance [20,21]. Subsequently, other authors confirmed these findings and showed that STZ treated rats in adulthood display the typical characteristics of T2D [22,23]. This animal model is mainly used to screen hypoglycaemic or antidiabetic agents [24-26] and also for hypolipidemic and oxidative stress related studies [27]. However, no studies attempted to use this model for investigating the Assessment of Type 2 Anti-Diabetes of *Barringtonia racemosa* (L.) Dichloromethane extract in streptozotocin (STZ) - Induced Diabetic Rats. Therefore, in this present study we evaluated STZ model for development of an agent for T2D.

Therefore, the choice of *Barringtonia racemosa* an evergreen mangrove plant, belonging to the family Lecythidaceae to cutely the menace of Diabetic disease is an option. The stem-bark and leaves have been traditionally used for anticancer, analgesic, antibacterial, anticolic and antifungal activities [28-37] this motivated us to study the antidiabetic potential of this plant extract.

Part of plant use	Treatment	Reference
Leaves	High blood pressure, itching, chicken pox itch, rheumatism febrifuge.	Kabir et al., 2013, Osman et al., 2015 [35,36]
Stem-bark	Fish poison, insecticide, skin disease,	Lim, 2012 [37].
Roots	Deobstruent, Relief in stomach ache	Isaac et al., 2018, Giesen et al., 2007, Manjunah 1948 [38-40].
Seeds	Tumors, fish poison, colic, febrifuge, vermifuge	Jayaweera et al., 1981[41].
Fruits	Poison wild pig, cough, asthma, diarrhea, eczema. Hemicrania, ophthalmia, cough, asthma, diarrhea	Thomas et al., 2002, Manjunah et al., 1948, Jayaweera et al., 1981, Giesen et al., 2007, Nadkami 1976.[34,40,41,39,42]
Part of plant (Antioxidant)		
Secondary Metabolites		
Leaves	Terpenoid,	Behbahani et al., 2007 [43]
Leaves, stem-bark	Flavonoid, Phenolic and phenolic acid	Kong et al., 2014 [44]
Fruits	Phenolic acid	Sulaiman and Ooni, 2014 [45]
(Antibacterial)		
Leaves	Mycobacterium smegmatic	Mmushi et al. (2010) [46]
Stem-bark	Staphylococcus aureus, Staphylococcus epidermidis	Saha et al., 2013 [47]
	Eschericia coli, Shigella dysentriae,	
	Vibrio cholerae, Proteus sp.	
Roots	Bacillus cereus, Salmonella typhy	Khan et al., 2001. [33]
(Antifungal)	Antimycobacterial Mycobacterium smegmatic	Mmushi et al. (2010). [46]
Leaves		
Leaves, stem-bark	Antifungus Fusarium sp., Tricoderma koningii,	Hussin et al. (2009). [48]
	Penicillium sp., Ganoderma tropicum,	
	Ganoderma lucidum, Aspergillus sp.,	
	Rhizopus sp.	
	Saprolegnia sp.	
(Anti-inflammatory)		
Fruits	Carrageenan-induced paw oedema, Formalin-induced paw oedema in albino rats.	Sikha et al. (2010). [49]
	Carrageenan-induced acute inflammation in rats	Patil et al. (2011). [50]
(α-glucosidase inhibitor)		
Seed	Yeast and intestinal	Gowri et al. (2007). [51]
	Glucosidase inhibition	Sulaiman and Ooi (2014).[45]
Fruits	Glucosidase inhibition Saccharomyces cerevisiae	Ponnappalli et al., 2015. [52]
(Analgesic)		
Stem-bark	Albino male rats, steroid.	Deraniyagala et al., 2003[53]
Fruits	Acetic acid-induced writhing response	Sikha et al. (2010). [49]
(Cytotoxicity)	Preliminary bioactive substances for Cancer cells proliferation.	Isaac et al., 2018[54,55]
Leaves, Stem-bark, Roots		

Table 1: Ethno Pharmacological uses and activity of *Barringtonia racemosa*.

Material and Methods

Materials

Chemicals, Drug and Kit

All of the analytical grade chemicals, drug and the kit were procured commercially. The Streptozotocin (STZ) (Medical Resource SDN BHD Kuching, Sarawak) and metformin hydrochloride ($C_4H_{11}N_5$) was decided as a positive control of the antidiabetic drug. The tested-diabetic rats were induced by the Streptozotocin (STZ) and were operated to measure the blood glucose level of the tested rats. All other chemicals were of analytical grade and were obtained from local companies.

Experimental Design

Albino rats were obtained from the National Center for Laboratory Animal Sciences, unimas, were injected intraperitoneal with 90mg/kg body weight STZ dissolved in 0.1M citrate buffer, pH 4.5 ($n = 42$). Control ($n = 6$) received normal diet. The rats were maintained on a normal diet in individual cages.

Animal Care

Animal care and protocols were in accordance with and approved by the Institutional Animal Ethics Committee (IAEC). Animals were housed in individual cages in a temperature and humidity controlled room

Sample Collection

The Leaves of *Barringtonia racemosa* was collected from Kampong Sarawak Malaysia by the river bank and Meranek at Meranek river bank in Kota-Samarahan Sarawak. Identification of the species was made by Prof Dr. Fasihuddin Bin Badruddin Ahmad and Prof Dr zaini B Assim. The samples were air-dried, cut into pieces and ground prior to analysis. It was then deposited at Department of Botany, Faculty of Resource Science and Technology, UNIMAS.

Preparation of Sample extracts

The collected *Barringtonia racemosa* were cut into thin slices and then air dried under shade for seven days. The dried leaves (2kg) were ground with an electric blender and sieved with 40 mm mesh sieve to get a fine powder. The powder was stored in a dark bottle at room temperature until use.

Extraction Method

The leaves of *Barringtonia racemosa* was extracted by the conventional solvent extraction method as described by Fasihuddin, et al. [56]. This was achieved by soaking the ground powdered leaves in non-polar, medium polar and polar solvents in the order of increasing polarity. A total of 2kg of the dried and ground Leaves of *Barringtonia racemosa* was extracted using cold soaking method with hexane (C_6H_{14}). The samples were soaked in the hexane with the ratio of 1:3 in 5 litres Erlenmeyer flasks at room temperature for 72 hours. The resulting hexane solution was then filtered using filter paper and the residue was re-extracted with fresh hexane for another 72 hours and filtered. All the extracts were combined and concentrated using the rotary evaporator of model Heidolph Laborota 4000 efficient, under reduced pressure to obtain the hexane crude extract. The residues were then re-extracted using the same procedure with dichloromethane (CH_2Cl_2), then ethyl acetate (C_2H_5COOH), chloroform ($CHCl_3$), and methanol (MeOH) to obtain various extract of sample of dichloromethane, ethyl acetate, chloroform and methanol crude extracts, respectively.

DPPH Assay

The DPPH (2,2-diphenyl-1-picrylhydrazyl, $C_{18}H_{12}N_5O_6$) as reported by Issac UJ [38] the leaves extract of *Barringtonia racemosa* was applied to evaluate the antioxidant activity to be $IC_{50} = 45.75$ which gives a base line potential of the activity of the extract against type 2 diabetic.

In Vivo Experiment

The healthy albino rats (150-200 g body weight) were conditioned in a cage for a week. After a week adaptation, the rats were separated into eight groups by setting: The Normal, negative and positive group. The remain five groups are the extract (dose) group of 100, 200, 300, 400, and 500mg/kg/bwt. Individual rat in each group was collected its blood on the 7th day and marked as a pre-treatment blood. The diabetic rat was generated by giving orally one mL of 50% (w/v) Streptozotocin (STZ) to each rat in each group [55] on the 8th and the 11th days. After a week since the Streptozotocin (STZ) (90mg/kg/bwt) given, the blood was collected from individual rat to check the diabetic rat according to the value blood glucose level ≥ 200 mg/dL [56]. This blood was noticeable as the blood

obtained before treatment. After finding out the diabetic rat, all rats were given orally: The aqueous metforminhydrochloride of 65 mg/kg/bwt in Positive control group, the aqueous tested extract of 100, 200, 300, 400 and 500mg/kg/bwt in the extracts treatment group respectively every day after 24hrs for 21 days.

Later on this point, the individual rat in each group was collected its blood. The blood was noticeable as the blood obtained after treatment. One day later, a rat in each group was selected to be sacrificed for histopathological observation on the kidney and pancreas

organs. The difference of blood glucose level was stated as an antidiabetic effect.

Histopathological Study

The kidney and pancreas organs were submerged in Neutral Buffered Formalin for a week and then histopathological investigations were performed [57]. The slices were stained with Haematoxylin Eosin (HE) and studied under Olympus binocular research microscope.

(Mean±SD mg/dl) Blood glucose level pre-treatment (Days)				
Treatment groups	Dose mg/kg	Before experiment	3 Pre-treatment	7pre-treatments
1. Normal	0.25ml	131.3±11.3	132.5±6.41	132.6±6.43
2. Negative	90mg/kg/bwt	414.3±13.5	414.5±5.32	415.7±5.41
3. Positive	65mg/kg/bwt	428.4±4.5	428.5±45.5	428.5±3.62
4. Extracts	100mg/kg/bwt	415.3±12.3	417±5.35*	418.7±52.42 ^d
5. Extracts	200 mg/kg/bwt	435.6±13.5	437.7±7.7	438.5±6.71
6. Extracts	300mg/kg/bwt	425.3±2.8	427.3±5.9*	435.9±7.62
7. Extracts	400 mg/kg/bwt	457.6±6.	457.9±1.3	458.2±4.31 ^d
8. Extracts	500 mg/kg/bwt	418.6±32.5*	433.4±3.5*	434.3±3.92 ^c

Table 2: Effect of *Barringtonia racemosa* Dichloromethane extracts on Mean Streptozotocin (STZ) of type 2 Diabetic Rats.

Value with superscripts c with a group along the row is significantly (P<0.05) higher than zero hours' blood glucose value with superscript d within the group along the row are significantly (P<0.05) lower than zero hours'

blood glucose value. While value with superscript * between groups along the column is significantly (P<0.05) lower than blood glucose value in the diabetic control.

(Mean±SD mg/dl) Blood glucose level post treatment (Days)							
Treatment groups	Dose mg/kg/bwt	0	3	7	14	21	28
1. Normal	0.25ml	132.6±6.43	123.5±6.4*	411.7±5.4a*	119.4±7.3*	120.0±5.5*	121.2±4.4b*
2. Negative	90mg/kg/bwt	415.7±5.14	388.5±5.3a*	122.6±6.4*	417.7±5.9a	427.2±8.6b*	456.7±6.4a
3. Positive	65mg/kg/bwt	428.5±3.62	243.5±45.5	222.5±3.6*	199.3±3.4c*	176.3±6.4	166.6±5.2a*
4. Extracts	100	418.7±52.42	326.4±5.3*	298.7±52.4a*	232.78±15.3	224.6±11.8	217.7±9.7
5. Extracts	200	438.5±6.71	327.7±7.7c*	311.5±6.7a*	255.5±4.4	233.3±4.5	115.2±8.5b
6. Extracts	300	435.9±7.62	287.3±5.9c*	235.9±7.6a*	218.7±7.4	205.8±3.7	176.9±6.4*
7. Extracts	400	458.2±4.31	277.9±1.3	201.8±4.3	195.3±7.3*	182.4±2.2	152.8±3.6*
8. Extracts	500	434.6±3.29	233.4±3.5	190.8±3.9	175.3±2.7*	153.4±5.5*	95.5±5.8*

Table 3: Effect of *Barringtonia racemosa* dichloromethane extracts on blood glucose level of Streptozotocin (STZ)-induced diabetic Rats.

Value with superscripts (a) with a group along the row is significantly (P<0.05) higher than zero hours' blood glucose value with superscript b within the group along the row are significantly (P<0.05) lower than zero hours'

blood glucose value. While value with superscript * between groups along the column is significantly (P<0.05) lower than blood glucose value in the diabetic control group.

Group	Dose mg/kg/bwt	Proximate convolution tubule score (Mean \pm SD)
1. Normal	-	-
2. Negative	90mg/kg/bwt	0.23 \pm 1.05
3. Positive	65mg/kg/bwt	0.45 \pm 0.63
4. extract	100	0.35 \pm 0.60
5. extract	200	0.32 \pm 0.63
6. Extract	300	0.34 \pm 0.61
7. Extract	400	0.33 \pm 0.59
8. Extract	500	0.32 \pm 0.62


Table 4: Proximate renal tubule cell score in the rats at various treatments.

P = (0.001) in proximal renal tubule cell count among the treatments based on one-way ANOVA analysis. Significant statistical difference.

Group	Dose mg/kg/bwt	Pancreatic β -cell (Mean \pm SD)
1. Normal	-	-
2. Negative	90mg/kg/bwt	463.20 \pm 10.73
3. Positive	65mg/kg/bwt	394.04 \pm 15.35
4. extract	100	382.01 \pm 10.66
5. extract	200	397.23 \pm 11.45
6. Extract	300	432.11 \pm 13.54
7. Extract	400	486.00 \pm 23.33
8. Extract	500	520.31 \pm 14.64

Table 5: Granulation of pancreatic β -cell at various treatments.

P < (0.001) in Pancreatic cell count among the treatment is based on one-way ANOVA analysis.






Figure 2: Histopathological performance of kidney in the normal rat (a), Metforminhydrochloride (b), diabetic rat + Dichloromethane extract with dose in 100mg kg⁻¹ b.wt. (c), diabetic rat + *Barringtonia* extract with a dose of 500 mg/kg/bwt. (d). Pink arrow: Proximal convoluted tubule, Blue arrow: Glomerulus.

Results

The *in vivo* experiment on the Streptozotocin (STZ)-induced T2-diabetic rats shown decreasing the blood glucose level along with increasing dose of the extract as shown in Table 3, The study of the proximate renal tubule cell scores in the rat's kidney at various treatment indicated renal damage within the normal range and as well as increase in the β -cell granulation (Table 4 and 5).

Discussion

Type 2 Diabetes is a metabolic disorder which has genetic and lifestyle etiology. A delayed treatment that is inadequate and when administered too late it predisposes the affected individual to the complications of diabetes. However, Streptozotocin is an agent that is frequently used to induce diabetes mellitus in albino rats [58,59]. It is generally accepted that the cytotoxicity produced by streptozotocin affects the DNA alkylation and subsequent activation of poly (ADP-ribose) synthetase. This causes rapid and dangerous depletion of

NAD in pancreatic islets [60,61]. It was also reported that the free radicals may play an essential role in the mechanism of β -cell damage and effect of streptozotocin induced-diabetes [62], thus the presence of antioxidant at 36.55 μ g/mL.

The progression of T2Diabetes begins with an impairment of glucose tolerance [63,64] and is often associated with a state of insulin resistance. Renal histopathologic observational data were described in semi-quantitative descriptive and scores with a scale of 0 to 2 [65]. The mark 0 states no lesions in the organ. The mark 1 suggests hydropic degeneration, fatty degeneration, karyomegaly and pycnosis. The mark 2 states the occurrence of necrosis. Each individual score was then counted up and the mean of the group was determined for comparison with controls, then, a mild (score 0), moderate (score 1) and severe (score 2) lesions were identified.

Table 4 presented proximate renal tubule cell score in the rats at various treatments, at 300mg/kg/bwt 0.34 \pm 0.61 the proximate convolution tubule score was

significant ($p>0.05$) which followed by 400mg/kg/bwt with 0.33 ± 0.59 , and 500mg/kg/bwt with 0.32 ± 0.62 when compared to the control

The kidney is a target organ of insulin. Insulin binds to the insulin receptors via the nephron [66], which is essential for the proper function of the nephron, glomerulus and tubule [67]. In insulin resistance, the insulin signalling cascade in the glomerulus seems to be impaired [68]. In diabetic conditions, insulin stimulation in the transportation of proximal renal tubules is impaired so that glucose reabsorption decreases and glucose is excreted through urine [67]. The administration of the *Barringtonia racemosa* extract improved the kidney and the visible cells in the proximal tubule was the same as absorbed in the normal rat (Figure 2).

However, plant extract as reported by Isaac, et al., is said to have antioxidant potential with IC_{50} value of $36.55\mu\text{g/mL}$, this fact suggested the ability of the extract to reduce free radical molecule which in this case may be contributed to the potential activity of this extract against T2D, as well as some result of some bioactive compound which are also responsible for its antibacterial, antifungal, analgesic activity, such as terpenes and flavonoid which has the ability to neutralize the DPPH molecule and also the properties as a free radical and a scavenger for other free radicals [69].

The result obtained from figure 3 showed that the Dichloromethane extract of *Barringtonia racemosa* given to the diabetic rats did not cause any significant change in the histologic structure of the kidney. Thus, agreed with [70]. This suggested that administration of the *Barringtonia racemosa* dichloromethane Leave extract in diabetic rats did not show specific damage to proximal renal tubular cells either. Thus, the bioactive compound contained in the extract did not cause damage to the kidney organs in the tested rats when compared to the controlling agent for type 2 diabetes.

However, the histopathologic images demonstrated that the pancreatic β -cell granulation was directly proportional to the given extract dose as shown in Table 5. The granulation of pancreatic β -cell at various treatments showed a remarkable significant result with increase in the concentration of the extract when compared to the control with 394.04 ± 15.35 and 382.01 ± 10.66 at 100mg/kg/bwt, 397.23 ± 11.45 at 200mg/kg/bwt, 432.11 ± 13.54 at 300mg/kg/bwt as well

as 400mg/kg/bwt and 500mg/kg/bwt with increase in the 486.00 ± 23.33 and 520.31 ± 14.64 respectively.

The number of β -cells enhancement is significant with $p<0.05$) for each treatment stated that the dichloromethane extract administered to hyperglycaemic rats, which invariably improve pancreatic β -cells and depresses necrosis or apoptosis of pancreatic β -cells when compared to metformin hydrochloride as shown in Figure 2. It was assumed that the modulatory effects of *Barringtonia racemosa* crude extract constituents on the blood glucose transporter by increasing insulin secretion, decreasing apoptosis and stimulating proliferation of pancreatic β -cells which agrees with the report of Zheng [71].

Conclusion

The bound flavonoids and some other bioactive component of *Barringtonia racemosa* leaves extract showed the strong antioxidant power and it displayed the type 2 anti-diabetes property. Administration of the extract with doses of 100 mg/kg/bwt. and 200 mg/kg/bwt. orally for 14 days was not causing the histopathologic disturbance on the tested rat kidney organ. Thus this plant extract should be used as an agent for type 2 diabetics.

Acknowledgement

The author Isaac John Umaru wish to appreciate Federal University of Wukari for Grant Fellowship and Universiti Malaysia Sarawak Natural Product Laboratory for their support.

Conflict of Interest

The authors declare that they do not have any conflict of interests.

Author's Contribution

Isaac John Umaru: Conceived, designed, performed the experiments and wrote the paper.
Hauwa A. Umaru: Provided reagents, data analyses and experimental tools analyses
Kerenhappuch I. Umaru: Materials and analysed the data.

Ethics

This original article contains unpublished material. The corresponding author states that all of the other

authors have read and agreed to the manuscript and no ethical issues are involved.

References

- Bastaki S (2005) Diabetes mellitus and its treatment. *Int J Diabetes Metab* 13: 111-134.
- Leahy JL, Hirsch IB, Peterson KA, Schneider D (2010) Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. *J Clin Endocrinol Metab* 95(9): 4206-4216.
- Rains JL, Jain SK (2011) Oxidative stress, insulin signalling and diabetes. *Free Radical Biol Med* 50: 567-575.
- Maritim AC, Sanders RA, Watkins JB (2003) Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol* 17(1): 24-38.
- Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K (2005) Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. *Invest Ophthalmol Vis Sci* 46(6): 2092-2099.
- Suryanarayana P, Saraswat M, Petrash JM, Reddy GB (2007) *Emblia officinalis* and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. *Mol Vis* 13: 1291-1297.
- Suryanarayana P, Satyanarayana A, Balakrishna N, Kumar PU, Reddy GB (2007) Effect of turmeric and curcumin on oxidative stress and antioxidant enzymes in streptozotocin-induced diabetic rat. *Med Sci Monit* 13(12): BR286-BR292.
- World Health Organization (2011) Diabetes: Key Facts, World Health Organization, Geneva, Switzerland.
- Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 87(1): 4-14.
- Zhang S, Chai FY, Yan H, Guo Y, Harding JJ (2008) Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. *Mol Vis* 14: 862-870.
- Drel VR, Xu W, Zhang J, Pavlov IA, Shevalye H, et al. (2009) Poly (adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. *Endocrinology* 150(12): 5273-5283.
- Siddiqui TA, Shadab Z, Nishat I, Ayasha N, Zehra Z, et al. (2003) Anticataract activity of Kohl-Chikni Dawa—a compound ophthalmic formulation of Unani medicine in alloxan-diabetic rats. *J Ethnopharmacol* 86(1): 109-12.
- Vats V, Yadav SP, Grover JK (2004) Ethanolic extract of *Ocimum sanctum* leaves partially attenuates streptozotocin-induced alterations in glycogen content and carbohydrate metabolism in rats. *J ethnopharmacol* 90(1): 155-160.
- Preet A, Gupta BL, Siddiqui MR, Yadava PK, Baquer NZ (2005) Restoration of ultrastructural and biochemical changes in alloxan-induced diabetic rat sciatic nerve on treatment with Na₃VO₄ and *Trigonella*—a promising antidiabetic agent. *Mol Cell Biochem* 278(1-2), 21-31.
- Saraswat M, Suryanarayana P, Reddy PY, Patil MA, Balakrishna N, et al. (2010) Antiglycating potential of *Zingiber officinalis* and delay of diabetic cataract in rats. *Mol Vis* 16: 1525.
- Schaffer SW, Wilson GL (1993) Insulin resistance and mechanical dysfunction in hearts of Wistar rats with streptozotocin-induced non-insulin-dependent diabetes mellitus. *Diabetologia* 36(3): 195-199.
- Takada J, Machado MA, Peres SB, Brito LC, Borges-Silva CN, et al. (2007) Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. *Metabolism* 56(7): 977-984.
- Anwer T, Sharma M, Pillai KK, Iqbal M (2008) Effect of *Withania somnifera* on Insulin Sensitivity in Non-Insulin-Dependent Diabetes Mellitus Rats. *Basic Clin Pharmacol Toxicol* 102(6): 498-503.
- Abdollahi M, Zuki AB, Goh YM, Rezaeizadeh A, Noordin MM (2011) Effects of *Momordica charantia* on pancreatic histopathological changes associated with streptozotocin-induced diabetes in neonatal rats. *Histol Histopathol* 26(1): 13-21.
- Movassat J, Portha B (2007) Early administration of keratinocyte growth factor improves β -cell regeneration in rat with streptozotocin-induced diabetes. *J Endocrinol* 195(2): 333-340.

21. Portha B, Levacher C, Picon L, Rosselin G (1974) Diabetogenic effect of streptozotocin in the rat during the perinatal period. *Diabetes* 23(11): 889-895.
22. Weir GC, Clore ET, Zmachinski CJ, Bonner-Weir S (1981) Islet secretion in a new experimental model for non-insulin-dependent diabetes. *Diabetes* 30(7): 590-595.
23. Iwase M, Kikuchi M, Nunoi K, Wakisaka M, Maki Y, et al. (1986) A new model of type 2 (non-insulin-dependent) diabetes mellitus in spontaneously hypertensive rats: diabetes induced by neonatal streptozotocin treatment. *Diabetologia* 29(11): 808-811.
24. Grill V, Westberg M, Ostenson CG (1987) B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia. *J Clin Invest* 80(3): 664-669.
25. Welsh N, Hellerström C (1990) In vitro restoration of insulin production in islets from adult rats treated neonatally with streptozotocin. *Endocrinology* 126(4): 1842-1848.
26. Hemmings SJ, Spafford D (2000) Neonatal STZ model of type II diabetes mellitus in the Fischer 344 rat: characteristics and assessment of the status of the hepatic adrenergic receptors. *Int J Biochem Cell Biol* 32(8): 905-919.
27. Farswan M, Mazumder PM, Percha V. (2009) Protective effect of *Cassia glauca* Linn. on the serum glucose and hepatic enzymes level in streptozotocin induced NIDDM in rats. *Indian J pharmacol* 41(1): 19-22.
28. Kim JO, Lee GD, Kwon JH, Kim KS (2009) Anti-diabetic effects of new herbal formula in neonatally streptozotocin-induced diabetic rats. *Biol Pharm Bull* 32(3): 421-426.
29. PariL, Ashokkumar N (2005) Effect of N-benzoyl-d-phenylalanine on lipid profile in liver of neonatal streptozotocin diabetic rats. *Fundam Clin Pharmacol*. 19(5): 563-568.
30. Suryanarayana P, Krishnaswamy K, Reddy GB (2003) Effect of curcumin on galactose-induced cataractogenesis in rats. *Mol Vis* 9(9): 223-230.
31. Song P, Wu Y, Xu J, Xie Z, Dong Y, et al. (2007) Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. *Circulation* 116(14): 1585-1595.
32. Zimmet P, Thomas CR (2003) Genotype, obesity and cardiovascular disease—has technical and social advancement outstripped evolution? *Journal of internal medicine* 254(2): 114-125.
33. Khan S, Jabbar A, Hasan CM, Rashid MA (2001) Antibacterial activity of *Barringtonia racemosa*. *Fitoterapia* 72(2): 162-164.
34. Thomas TJ, Panikkar B, Subramoniam A, Nair MK, Panikkar KR (2002) Antitumour property and toxicity of *Barringtonia racemosa* Roxb seed extract in mice. *J Ethnopharmacol* 82(2-3): 223-227.
35. Kabir MZ, Rahman SM, Islam MR, Paul PK, Rahman S (2013) A review on a mangrove species from the Sundarbans, Bangladesh: *Barringtonia racemosa* (L.) roxb. *Am Eurasian J Sustainable Agric* 7: 356-372.
36. Osman NI., Sidik NJ, Awal A (2015) Pharmacological activities of *Barringtonia racemosa* L. (Putat), a tropical medicinal plant species. *J Pharm Sci Res* 7: 185-188.
37. Lim TK (2012) *Barringtonia racemosa*. In: *Edible Medicinal and Non-Medicinal Plants*, Lim TK (Ed.), Springer Science and Business Media BV, Dordrecht, Heidelberg, London and New York, pp: 114-121.
38. Umaru IJ, Ahmed FB, Umaru HA, Umaru KI (2018) *Barringtonia racemosa*: phytochemical, pharmacological, biotechnological, botanical, traditional use and agronomical aspects. *World Journal of Pharmacy and Pharmaceutical Sciences* 7(8): 78-121.
39. Giesen W, Wulfraat S, Zieren M, Scholten L(2007) *Barringtonia Racemosa*. In: *Mangrove Guidebook for Southeast Asia*, FAO and Wetlands International, Bangkok, Thailand and Wageningen, Netherlands.
40. Manjunath BL (1948) *The Wealth of India: A Dictionary of Indian Raw Materials and Industrial Products*. 1st Edn., Council of Scientific and Industrial Research, New Delhi, pp: 159.

41. Jayaweera DMA (1981) Medicinal plants (indigenous and exotic) used in Ceylon, part III. The National Science Council of Sri Lanka, Colombo.
42. Nadkarni AK (1976) Dr. KM Nadakarni's Indian Materia Medica. 3rd Ed., Popular Prakashan Ltd., Bombay, pp: 177.
43. Behbahani M, Ali AM, Muse R, Mohammad NB (2007) Anti-oxidant and anti-inflammatory activities of leaves of *Barringtonia racemosa*. *J Med Plants Res* 1: 95-102.
44. Kong KW, Mat-Junit S, Ismail A, Aminudin N, Abdul-Aziz A (2014) Polyphenols in *Barringtonia racemosa* and their protection against oxidation of LDL, serum and haemoglobin. *Food Chem* 146: 85-93.
45. Sulaiman SF, Ooi KKL (2014) Antioxidant and α -glucosidase inhibitory activities of 40 tropical juices from Malaysia and identification of phenolics from the bioactive fruit juices of *Barringtonia racemosa* and *Phyllanthus acidus*. *J Agric Food Chem* 62(39): 9576-9585.
46. Mmushi T, Masoko P, Mdee L, Mokgotho M, Mampuru LJ, et al. (2010) Anti-mycobacterial evaluation of fifteen medicinal plants in South Africa. *Afr J Tradit Complement Altern Med* 7(1): 34-39.
47. Saha S, Sarkar KK, Hossain ML, Hossain A, Barman AK, et al. (2013) Bioactivity studies on *Barringtonia racemosa* (Lam.) Bark. *Pharmacol.m OnLine* 1: 93-100.
48. Hussin NM, Muse R, Ahmad S, Ramli j, Mahmood M, et al. (2009) Antifungal activity of extracts and phenolic compounds from *Barringtonia racemosa* L. (Lecythidaceae). *Afr J Biotechnol* 8(12): 2835-2842.
49. Sikha P, Latha PG, Suja SR, Anuja GI, Shyamal S, et al. (2010) Anti-inflammatory and analgesic activity of *Barringtonia racemosa* Roxb. *Fruits. Ind J Nat Prod Resour* 1(3): 356-361.
50. Patil KR, Patil CR, Jadhav RB, Mahajan VK, Raosaheb P (2011) Anti-arthritis activity of bartogenic acid isolated from fruits of *Barringtonia racemosa* Roxb. (Lecythidaceae). *Evidence-Based Complementary Alternative Med* 2011: 1-7.
51. Gowri PM, Tiwari AK, Ali AZ, Rao JM (2007) Inhibition of α -glucosidase and amylase by bartogenic acid isolated from *Barringtonia racemosa* Robx. seeds. *Phytotherapy Res* 21: 796-799.
52. Ponnappalli MG, Sukki S, Annam SCVAR, Ankireddy M, Tirunagari H, et al. (2015) α -Glucosidase inhibitory monoacylated polyhydroxytriterpenoids from the fruits of *Barringtonia racemosa*. *Tetrahedron Lett* 56: 1570-1574.
53. Deraniyagala SA, Ratnasooriya WD, Goonasekara CL (2003) Antinociceptive effect and toxicological study of the aqueous bark extract of *Barringtonia racemosa* on rats. *J Ethnopharmacol* 86(1): 21-26.
54. ADA (2015) Classification and diagnosis of diabetes. *Diabetes Care* 38: 58-516
55. Umaru IJ, Badruddin FA, Assim ZB, Umaru HA (2018) Cytotoxicity (Brine shrimp Lethality Bioassay) of *Barringtonia racemosa* Leaves, Stem-Bark and Root Extract. *Journal of Biotechnology and Bioengineering*, 2(2): 45-50.
56. Fasihuddin BA, Sallehuddin NKNM, Assim Z (2010) Chemical constituents and antiviral study of *Goniothalamus velutinus*. *Malaysian Journal of Fundamental and Applied Sciences* 6(1): 73-76.
57. Arul B, Kothai R, Christina AJM (2006) Antihyperglycemic and hypoglycemic effect of *Bougainvillea spectabilis* Linn. In normal and glucoseinduced diabetic rats. *Hamdard Med* 49: 18-21.
58. Candasamy M, Murthy TE, Gubiyappa KS, Chellappan DK, Gupta G (2014) Alteration of glucose lowering effect of glibenclamide on single and multiple treatments with fenofibrate in experimental rats and rabbit models. *J Basic Clin Pharmacy* 5(3): 62-67.
59. Spitalnik PF (2016) Histology laboratory manual 2016-2017. College of Physicians and Surgeons, Columbia University, New York.
60. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in β -cells of the rat pancreas. *Physiol Res* 50(6): 537-46.
61. Yamagishi N, Nakayama K, Wakatsuki T, Hatayama T (2001) Characteristic changes of stress protein expression in streptozotocin induced diabetic rats. *Life Sci* 9(22): 2603-2609.

62. Bennet RA, Pegg AE (1981) Alkylation of DNA in rat tissues following administration of streptozotocin. *Cancer Res* 41(7): 2786-90.
63. Bolzan AD, Bianchi Ms (2002) Genotoxicity of streptozotocin. *Mutat Res* 512(2-3): 121-134.
64. Ohkuwa T, Sato Y, Naoi M (1995) Hydroxyl radical formation in diabetic rat induced by streptozotocin. *Life Sci* 56(21): 1789-1798.
65. Suhita NLPR, Sudira IW, Winaya IBO (2013) Histopathological kidney of rat white the effect of the pegagan (*Centella asiatica*) extract against peroral. *Buletin Veteriner Udayana* 5(2): 71-78.
66. Nakamura R, Emmanouel DS, Katz AI (1983) Insulin binding sites in various segments of the rabbit nephron. *J Clin Invest* 72(1): 388-392.
67. Hale LJ, Coward RJ (2013) The insulin receptor and the kidney. *Curr Opin Nephrol Hypertens* 22(1): 100-106.
68. Lay A, Coward RJ (2014) Recent advances in our understanding of insulin signalling to the podocyte. *Nephrol Dial Transplant* 29(6): 1127-1133.
69. Horita S, Nakamura M, Suzuki M, Satoh N, Suzuki A, et al. (2017) The role of renal proximal tubule transport in the regulation of blood pressure. *Kidney Res Clin Pract* 36(1): 12-21.
70. Khoshnoud S, Mohseni Kouchesfahani H, Nabiuni M (2017) Evaluation of the protective effect of hydroalcoholic extract of raspberry fruit on aquaporin1 expression in rats' kidney treated by methotrexate. *Cell J* 19(2): 306-313.
71. Zheng S, Zhao M, Wu Y, Wang Z, Ren Y (2016) Suppression of pancreatic beta cell apoptosis by Danzhi Jiangtang capsule contributes to the attenuation of type 1 diabetes in rats. *BMC Complement Altern Med* 16: 31-41.

